A Prior Auth Truce? Novartis Willing to Embrace ICER-Like Price Determinations For Increased Access

 
• By Sarah Karlin-Smith
  
White Truce Flag
Novartis Wants Manufacturers And Payers To Halt Escalating Cost Of Utilization Management. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access